Home/ Stocks/ FBRX

Forte Biosciences, Inc. Common Stock

FBRX XNAS

$24.02 -2.77 (-10.58%) ▼ 15-min delayed

Open

$25.95

High

$25.97

Low

$23.53

Volume

344.8K

Market Cap

$491.90M

About Forte Biosciences, Inc. Common Stock

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 19 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$2.71M	$-69,375,000	$-4.71
FY 2025	$2.71M	$-69,375,000	$-4.71
Q3 2025	$0	$-17,682,000	$-0.99
Q2 2025	$0	$-11,249,000	$-0.96

Related Market News

No specific coverage for FBRX yet. Check out our latest market news or earnings calendar.

Get FBRX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Forte Biosciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.